Harbin Pharmaceutical Group Co (SHSE:600664) Total Tax Payable: ¥135 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600664 Harbin Pharmaceutical Group Co Ltd SHSE:600664
58 GF Score
Price ¥7.78
GF Value ¥3.65
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Harbin Pharmaceutical Group Co Total Tax Payable?

Harbin Pharmaceutical Group Co SHSE:600664 -9.01% 58 Total Tax Payable is ¥135 Mil as of Jun. 2026. GuruFocus rates SHSE:600664 with a GF Score™ of 58/100 and a GF Value™ of ¥3.65 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Harbin Pharmaceutical Group Co's Total Tax Payable for the quarter that ended in Jun. 2026 was ¥135 Mil.

Harbin Pharmaceutical Group Co's quarterly Total Tax Payable increased from Dec. 2025 (¥82 Mil) to Mar. 2026 (¥137 Mil) but then declined from Mar. 2026 (¥137 Mil) to Jun. 2026 (¥135 Mil).

Harbin Pharmaceutical Group Co's annual Total Tax Payable declined from Dec. 2023 (¥114 Mil) to Dec. 2024 (¥105 Mil) and declined from Dec. 2024 (¥105 Mil) to Dec. 2025 (¥82 Mil).

Harbin Pharmaceutical Group Co Total Tax Payable Related Terms

Harbin Pharmaceutical Group Co Total Tax Payable Historical Data

* Premium members only.

The historical data trend for Harbin Pharmaceutical Group Co's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harbin Pharmaceutical Group Co Total Tax Payable Chart

Harbin Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Tax Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 144.16 212.02 114.50 104.66 81.82

Harbin Pharmaceutical Group Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Tax Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 102.58 110.86 81.82 137.41 134.77
SHSE:600664
58GF Score
Harbin Pharmaceutical Group Co Ltd SHSE:600664
Total Tax Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harbin Pharmaceutical Group Co Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Frequently Asked Questions Learn more about Total Tax Payable →
What does a Total Tax Payable of ¥135 Mil mean?
Harbin Pharmaceutical Group Co (SHSE:600664) has a Total Tax Payable of ¥135 Mil as of Jun. 2026. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Harbin Pharmaceutical Group Co and its competitors.
Is Harbin Pharmaceutical Group Co's Total Tax Payable too high?
Harbin Pharmaceutical Group Co's current Total Tax Payable is ¥135 Mil. Overall, Harbin Pharmaceutical Group Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Harbin Pharmaceutical Group Co's Total Tax Payable compare to ZTS?
Harbin Pharmaceutical Group Co's Total Tax Payable of ¥135 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Tax Payable for a Drug Manufacturers company?
A good Total Tax Payable depends on the Drug Manufacturers industry context. However, Total Tax Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Tax Payable mean?
A high Total Tax Payable can signal that a stock is expensive relative to its fundamentals. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Harbin Pharmaceutical Group Co and its competitors. Harbin Pharmaceutical Group Co's current Total Tax Payable is ¥135 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harbin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co (SHSE:600664) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥3.65, compared to a current price of ¥7.78 — trading 113.2% above its estimated fair value. The current Total Tax Payable is ¥135 Mil. Harbin Pharmaceutical Group Co's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Tax Payable calculated?
Total Tax Payable is calculated from a company's financial statements. For Harbin Pharmaceutical Group Co (SHSE:600664), the current Total Tax Payable is ¥135 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harbin Pharmaceutical Group Co (SHSE:600664) Overvalued in 2026?

Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co stock appears to be overvalued. The current stock price of ¥7.78 is trading 113.2% above its estimated GF Value™ of ¥3.65. GuruFocus considers Harbin Pharmaceutical Group Co to be Significantly Overvalued.

Key valuation signals for SHSE:600664:

  • Total Tax Payable: ¥135 Mil
  • GF Value™: ¥3.65 vs. price of ¥7.78 (113.2% above fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the SHSE:600664 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harbin Pharmaceutical Group Co Business Description

Address Xi\'an Street West, People \'s Development Zone Baoan Road South, Heilongjiang Province, Harbin, CHN, 150018
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
58GF Score

Get the complete analysis for SHSE:600664

Total Tax Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥7.78
Price
¥3.65
GF Value